ABIO - ARCA biopharma Inc Stock Price, Fair Value and News

3.12USD+0.05 (+1.63%)Market Closed

Market Summary

USD3.12+0.05

Market Closed

1.63%

ABIO Alerts

1 major insider buys recently.

JANUS HENDERSON GROUP PLC reported owning 10.2% of ABIO [2024-07-05]

ABIO Stock Price

View Fullscreen

ABIO RSI Chart

ABIO Valuation

Market Cap

45.3M

Price/Earnings (Trailing)

-7.54

Price/Sales (Trailing)

22.86

EV/EBITDA

-0.79

Price/Free Cashflow

-9.15

ABIO Price/Sales (Trailing)

ABIO Profitability

EBT Margin

-1027.63%

Return on Equity

-17.09%

Return on Assets

-16.35%

Free Cashflow Yield

-10.93%

ABIO Fundamentals

ABIO Revenue

Revenue (TTM)

2.0M

Rev. Growth (Yr)

5.11%

Rev. Growth (Qtr)

-5.59%

ABIO Earnings

Earnings (TTM)

-6.0M

Earnings Growth (Yr)

-49.26%

Earnings Growth (Qtr)

-84.48%

Breaking Down ABIO Revenue

Last 7 days

-5.2%

Last 30 days

-10.1%

Last 90 days

-12.8%

Trailing 12 Months

52.9%

How does ABIO drawdown profile look like?

ABIO Financial Health

Current Ratio

23.19

ABIO Investor Care

Shares Dilution (1Y)

0.67%

Diluted EPS (TTM)

-0.42

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	2.0M	0	0	0
2023	1.1M	1.5M	1.8M	2.0M
2022	0	83.0K	302.0K	672.0K
2021	6.0K	7.0K	10.0K	13.0K
2020	158.0K	112.0K	63.0K	28.0K
2019	159.0K	164.0K	174.0K	172.0K
2018	163.0K	167.0K	163.0K	162.0K
2017	193.0K	185.0K	176.0K	167.0K
2016	34.0K	79.0K	128.0K	169.0K
2015	6.0K	6.0K	8.0K	14.0K
2014	6.0K	7.0K	7.0K	7.0K
2013	0	4.0K	6.0K	6.0K
2012	0	3.0K	4.0K	0
2011	572.8K	382.5K	192.3K	2.0K
2010	0	0	0	763.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About ARCA biopharma Inc

ARCA biopharma, Inc., a clinical development stage biopharmaceutical company, engages in the development and commercialization of genetically targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with chronic heart failure. It is also developing Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. ARCA biopharma, Inc. has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. The company was founded in 2004 and is headquartered in Westminster, Colorado.

CEO	Dr. Michael R. Bristow M.D., Ph.D.
WEBSITE	arcabio.com
INDUSTRY	Biotechnology
EMPLOYEES	5

ARCA biopharma Inc Frequently Asked Questions

What is the ticker symbol for ARCA biopharma Inc? What does ABIO stand for in stocks?

ABIO is the stock ticker symbol of ARCA biopharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of ARCA biopharma Inc (ABIO)?

As of Fri Jul 26 2024, market cap of ARCA biopharma Inc is 45.26 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ABIO stock?

You can check ABIO's fair value in chart for subscribers.

Is ARCA biopharma Inc a good stock to buy?

The fair value guage provides a quick view whether ABIO is over valued or under valued. Whether ARCA biopharma Inc is cheap or expensive depends on the assumptions which impact ARCA biopharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABIO.

What is ARCA biopharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 26 2024, ABIO's PE ratio (Price to Earnings) is -7.54 and Price to Sales (PS) ratio is 22.86. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABIO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on ARCA biopharma Inc's stock?

In the past 10 years, ARCA biopharma Inc has provided -0.332 (multiply by 100 for percentage) rate of return.